Valeant’s Winners and Losers

The troubled drugmaker takes another plunge as it reduces guidance. Here’s a quick survey of the firms that are taking a bath and those that look like geniuses.

Was Tuesday capitulation day for shareholders of Valeant Pharmaceuticals International, which lost nearly half its value after cutting its revenue and earnings guidance for the rest of the year amid fears that it may default on its debt? Was this the day its longtime bulls finally surrendered and liquidated their positions in the beleagured Laval, Quebec–based drugmaker?

We probably won’t know for sure until mid-May, when hedge funds disclose their first-quarter holdings with regulators.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.